Aquestive Therapeutics, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.aquestive.com

Safety Score

Market Cap $332.37M
Debt $45.00M
Cash $77.89M
EV $299.48M
FCF -$34.37M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$35.19M
EBIT	-$25.20M
ROA	-23%
FCF	-$34.37M
Equity	-$45.42M
Growth Stability	1
PE	-9.44
PB	-7.32
P/FCF	-9.67
P/S	5.64
Price/Cash	0.23
Debt/Equity	-0.99
Debt/FCF	-1.31
Net Margins	-59%
Gross Margins	69%
Op. Margins	-43%
Sales Growth YoY	4%
Sales Growth QoQ	-33%
Sales CAGR	-4%
FCF CAGR	0%

Earnings Growth YoY	466%
Earnings Growth QoQ	319%
Sales CAGR 5Y	1%
Earnings CAGR 3Y	5%
Sales CAGR 3Y	5%
Market Cap	$332.37M
Revenue	$58.90M
Assets	$109.96M
Total Debt	$45.00M
Cash	$77.89M
Shares Outstanding	85.22M
EV	299.48M
Safety Score	35%
Working Capital	81.42M
Current Ratio	6.37
Gross Profit	$40.87M
Shares Growth 3y	34%
Equity Growth QoQ	28%
Equity Growth YoY	-56%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

SEC Filings

Direct access to Aquestive Therapeutics, Inc. (AQST) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Aquestive Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Aquestive Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Aquestive Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Aquestive Therapeutics, Inc..

Years

Calculation mode

= -$346M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$34M	-$34M	-$34M	-$34M	-$34M	-$35M	-$35M	-$35M	-$35M	-$35M	-$35M	-$347M
DCF		-$31M	-$28M	-$26M	-$24M	-$21M	-$20M	-$18M	-$16M	-$15M	-$13M	-$134M
Value	-$346M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-17%	-91%	-126%	-122%	-139%	-114%	-16%	-59%
ROA	-	-56%	-67%	-68%	-56%	-74%	-13%	-23%
ROE	-	-609%	1K%	115%	86%	46%	7%	-

Bad Net Margins (-59.27%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-1.15	-1.12	-	-3.09	-6.1	-1.31
Debt over Equity	-	-	-11.43	-1.06	-	-0.28	-0.42	-0.99
Growth Stability	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-1.31)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.99)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	1%	-22%	-13%	11%	-6%	6%	1%
Earnings YoY growth	-	437%	8%	-16%	26%	-23%	-86%	-
Equity YoY growth	-	-115%	-161%	692%	69%	44%	-10%	-
FCF YoY growth	-	-494%	311%	-24%	-26%	-68%	-32%	-